fbpx

EMERGERS

Equity Research of
Nordic Growth Companies

MOTION DISPLAY: Strong gross margin driving another profitable quarter  

2024-08-30• Analys, Research

MODI reported Q2’24 sales largely in line with last year, at SEK 7.4m compared to SEK 7.6m in Q2’23. The gross margin increased by 6ppt...

Read More →

PROLIGHT: Pre-validation readout in Q4 sets stage for multicenter trial in 2025

2024-08-29• Analys, Research

Supported by the latest troponin data generated from whole blood samples on the final commercial cartridge design, Prolight is now ready to...

Read More →

NANEXA: NEX-22 Progress, Revaluation and Financing

2024-08-28• Analys, Research

After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22...

Read More →

CRUNCHFISH: Three avenues to address the strained financing

2024-08-26• Analys, Research

While the commercialization of Crunchfish’s solution for offline payments has shown a longer sales cycle than expected, the company...

Read More →

Agtira AB: Big launch and a capital-light expansion in the cards

2024-08-19• Analys, Research

In terms of financials, Q2 was largely a repeat of Q1, with one-off replanting and remediation costs from the Q1 disease affecting the...

Read More →

GRANGEX: Updated DFS confirming viability to produce high-grade iron ore at Dannemora

2024-06-17• Analys, Research

The announcement of the updated DFS for Dannemora showed, as expected, higher CAPEX and OPEX compared to the FS announced in December 2022,...

Read More →

PROLIGHT: SEK 17m UK grant a welcome external validation

2024-05-20• Analys, Research

Prolight’s report for Q1’24 did not reveal any particular surprises. The positive SEK 5.6m revision to the FY’23 result stemming from...

Read More →

AGTIRA: Mixed start to pivotal 2024

2024-05-15• Analys, Research

As announced already in February, capacity utilization and turnover in Q1 were weighed down by the plant disease in Härnösand, with a...

Read More →

NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential

2024-05-10• Analys, Research

Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved rather uneventful. The subsequent CMD...

Read More →

GRANGEX: Striking renegotiation of Sydvaranger acquisition setting GRANGEX up for an eventful 2024

2024-05-08• Analys, Research

With a striking renegotiation of the final purchase agreement for Sydvaranger, reducing the initial payment from USD 1+19m to USD 1+0.5m,...

Read More →

Actionable Investment Research | Sectors & Themes | Shorts and Frauds

Widmark Research 

CONTACT

Johan Widmark

Mail: johan@emergers.se
Tel: +46739196641

Östermalmsgatan 26A
114 26 Stockholm, Sweden

For new research on growth stocks, sign up to our newsletter